Why SciSparc Is Trading Higher By 68%, Here Are 48 Stocks Moving In Wednesday''s Mid-Day Session
Gainers Akerna Corp. (NASDAQ: KERN ) shares rose 81.2% to $0.2355 after gaining 8% on Tuesday. SciSparc Ltd. (NASDAQ: SPRC ) gained 68% to $1.3101 after the company announced it entered into an agreement to acquire Wellution for $20 million. bioAffinity Technologies, Inc. (NASDAQ: BIAF ) shares jumped 51.2% to $6.27 after the company announced publication of its research in high-throughput flow cytometry analysis of sputum in PLOS ONE. My Size, Inc. (NASDAQ: MYSZ ) rose 44% to $0.3194. ThermoGenesis Holdings, Inc. (NASDAQ: THMO ) surged 36.8% to $0.3090. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) jumped 28.6% to $0.2992. Fast Radius, Inc. (NASDAQ: FSRD ) gained 23.6% to $0.6799. NeuroOne Medical Technologies Corporation (NASDAQ: NMTC ) rose 23% to $2.2269. VistaGen Therapeutics, Inc. (NASDAQ: VTGN ) jumped 19.6% to $0.2259. VistaGen Therapeutics recently announced the completion of an interim analysis of its PALISADE-2 Phase 3 clinical trial of PH94B. Tenax Therapeutics, Inc. (NASDAQ: TENX ) surged 18% to $0.24.
Why SciSparc Is Trading Higher By 68%, Here Are 48 Stocks Moving In Wednesday''s Mid-Day Session
Gainers Akerna Corp. (NASDAQ: KERN ) shares rose 81.2% to $0.2355 after gaining 8% on Tuesday. SciSparc Ltd. (NASDAQ: SPRC ) gained 68% to $1.3101 after the company announced it entered into an agreement to acquire Wellution for $20 million. bioAffinity Technologies, Inc. (NASDAQ: BIAF ) shares jumped 51.2% to $6.27 after the company announced publication of its research in high-throughput flow cytometry analysis of sputum in PLOS ONE. My Size, Inc. (NASDAQ: MYSZ ) rose 44% to $0.3194. ThermoGenesis Holdings, Inc. (NASDAQ: THMO ) surged 36.8% to $0.3090. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) jumped 28.6% to $0.2992. Fast Radius, Inc. (NASDAQ: FSRD ) gained 23.6% to $0.6799. NeuroOne Medical Technologies Corporation (NASDAQ: NMTC ) rose 23% to $2.2269. VistaGen Therapeutics, Inc. (NASDAQ: VTGN ) jumped 19.6% to $0.2259. VistaGen Therapeutics recently announced the completion of an interim analysis of its PALISADE-2 Phase 3 clinical trial of PH94B. Tenax Therapeutics, Inc. (NASDAQ: TENX ) surged 18% to $0.24.